1. Home
  2. MNKD

MNKD

MannKind Corporation

Logo MannKind Corporation

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Founded: 1991 Country:
United States
United States
Employees: N/A City: DANBURY
Market Cap: 1.1B IPO Year: 2004
Target Price: $8.00 AVG Volume (30 days): 3.0M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.04 EPS Growth: N/A
52 Week Low/High: $3.17 - $5.75 Next Earning Date: 05-07-2024
Revenue: $198,962,000 Revenue Growth: 99.42%
Revenue Growth (this year): 33.25% Revenue Growth (next year): 23.08%

Share on Social Networks: